E-resources
-
Augello, Giuseppa; Emma, Maria Rita; Cusimano, Antonella; Azzolina, Antonina; Mongiovì, Sarah; Puleio, Roberto; Cassata, Giovanni; Gulino, Alessandro; Belmonte, Beatrice; Gramignoli, Roberto; Strom, Stephen C.; McCubrey, James A.; Montalto, Giuseppe; Cervello, Melchiorre
International journal of cancer, 15 May 2019, Volume: 144, Issue: 10Journal Article
Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter‐ and intra‐tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well‐characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but its role in hepatocarcinogenesis remains unclear. Here, we analyzed HSP90 expression in primary human HCC tissues and evaluated the antitumor effects of AUY922 in vitro as well as in vivo. HSP90 expression was significantly higher in HCC tissues than in cirrhotic peritumoral liver tissues. AUY922 treatment reduced the cell proliferation and viability of HCC cells in a dose‐dependent manner, but did not do so for normal human primary hepatocytes. AUY922 treatment led to the upregulation of HSP70 and the simultaneous depletion of HSP90 client proteins. In addition, in a cell type‐dependent manner, treatment induced either both caspase‐dependent β‐catenin cleavage and the upregulation of p53, or Mcl‐1 expression, or NUPR1 expression, which contributed to the increased efficacy of, or resistance to, treatment. Finally, in vivo AUY922 inhibited tumor growth in a xenograft model. In conclusion, HSP90 is a promising therapeutic target in HCC, and AUY922 could be a drug candidate for its treatment. What's new? Hepatocellular carcinoma (HCC) exhibits vast molecular heterogeneity, suggesting that therapies aimed against targets that interact with multiple signaling pathways could be key to improving HCC outcome. Here, heat shock protein 90 (HSP90), a modulator of numerous signaling components, was found to be highly expressed in HCC. AUY922, an HSP90 inhibitor, blocked HCC cell growth in vitro and, in HepG2 liver carcinoma cells, induced apoptosis via caspase activation and β‐catenin fragmentation. These effects were not observed in Huh7 or SNU475 HCC cell lines. AUY922 also reduced tumor growth in vivo, marking HSP90 as a promising therapeutic target in HCC.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.